Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:biologic_medication |
| gptkbp:administeredBy |
ribavirin
|
| gptkbp:approvedBy |
2001
|
| gptkbp:ATCCode |
L03AB60
|
| gptkbp:brand |
gptkb:PegIntron
gptkb:Pegasys |
| gptkbp:contraindication |
autoimmune hepatitis
decompensated liver disease |
| gptkbp:developedBy |
gptkb:Schering-Plough
gptkb:Roche |
| gptkbp:eliminationHalfLife |
about 50 hours
|
| gptkbp:hasComponent |
gptkb:plastic
gptkb:interferon_alfa |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
gptkb:antiviral_drug
gptkb:immunotherapy |
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:sideEffect |
gptkb:depression
gptkb:anemia neutropenia flu-like symptoms |
| gptkbp:status |
FDA approved
|
| gptkbp:usedFor |
gptkb:hepatitis_C
gptkb:hepatitis_B |
| gptkbp:bfsParent |
gptkb:Sovaldi
|
| gptkbp:bfsLayer |
6
|
| https://www.w3.org/2000/01/rdf-schema#label |
peginterferon alfa
|